APA (7th ed.) Citation

H, P., J, R., C, F., C, P., G, J., & JR, J. (2026). The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: A systematic review. Leukemia & lymphoma, 67(1), 7. https://doi.org/10.1080/10428194.2025.2560085

Chicago Style (17th ed.) Citation

H, Park, Robinson J, Flanagan C, Pawlyn C, Jackson G, and Jones JR. "The Risk of Second Primary Malignancies in Patients Receiving T-cell Directed Therapies for Multiple Myeloma: A Systematic Review." Leukemia & Lymphoma 67, no. 1 (2026): 7. https://doi.org/10.1080/10428194.2025.2560085.

MLA (9th ed.) Citation

H, Park, et al. "The Risk of Second Primary Malignancies in Patients Receiving T-cell Directed Therapies for Multiple Myeloma: A Systematic Review." Leukemia & Lymphoma, vol. 67, no. 1, 2026, p. 7, https://doi.org/10.1080/10428194.2025.2560085.